Probiotic in Dry Eye Syndromes

Status Completed

Clinical Trial Summary

This study will evaluate efficacy and safety of systemic and ophthalmic probiotic from bacterial lysate of Lactobacillus sakei on microbiota, immunological and clinical outcomes of patients with Dry Eye Syndrome.

Clinical Trial Description

The ocular surface is comprised of the cornea and its overlying tissue, the conjunctiva. The ocular surface is continuously exposed to the external environment and, therefore, to different microbial species. A resident ocular surface microbiota has been found in various studies. Although little is known so far, some elements of this microbiota and/or its metabolites could represent protective cofactosr in the pathogenesis of common ocular diseases. On the other hand, the gut microbiota is known to influence host homeostasis in distal tissues, such as brain (gut-barin axis), lungs (gut-lungs axis) and skin (gut-skin axis). However, little is known about distal effects of the gut microbiota on the ocular surface. In this study we sought to evaluate the efficacy and safety aspects of L.sakei as both ophtalmic probiotic lysate and oral live probiotic on Dry Eye Syndrome, using a factorial design, against placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04938908
Study type	Interventional
Source	Shiraz University of Medical Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	July 1, 2021
Completion date	July 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02597803` - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1	Phase 2/Phase 3
Completed	`NCT02522312` - A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients	N/A
Completed	`NCT01863368` - Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining	N/A
Completed	`NCT01753752` - Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation	Phase 2
Completed	`NCT01753687` - Correlation of Different Signs for Assessment of Dry Eye Syndrome	N/A
Completed	`NCT01212471` - A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease	Phase 3
Completed	`NCT01198782` - Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%	Phase 4
Completed	`NCT01162954` - Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers	Phase 1
Completed	`NCT00535054` - Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms	N/A
Completed	`NCT00544713` - Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery	N/A
Completed	`NCT00344721` - A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome	N/A
Completed	`NCT03830359` - Efficacy, Safety of T2769 in Dry Eye Disease	N/A
Completed	`NCT04139122` - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease	Phase 1/Phase 2
Completed	`NCT02758327` - Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops	Phase 4
Completed	`NCT01970917` - Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects	Phase 4
Completed	`NCT02066051` - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD	N/A
Completed	`NCT02092207` - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT01541891` - Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT01252121` - Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline	N/A
Completed	`NCT00765804` - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye	Phase 2